Peer-Reviewed Articles

eSource Records in Clinical Research: Keeping it Simple

By Jules T. Mitchel, Jonathan Helfgott, Tom Haag, Silvana Cappi, Imogene McCanless, Yong Joong Kim, Joonhyuk Choi, Timothy Cho, Dean A. Gittleman

There has been a recent thrust within the pharmaceutical industry to promote the transformation of the clinical trial process.

Determining Participation in Ukraine

By Nataliia Vietchinkina

Survey shows what keeps Ukrainians away from clinical trials.

Designing Quality Improvement Registries

By Michelle Leavy, Daniel M. Campion

Focusing on efficiency and sustainability from the start improves the likelihood of success.

The Current Status of Risk-Based Monitoring

By Linda B. Sullivan

A comprehensive survey by Metrics Champion Consortium


TransCelerate’s eLabeling Initiative

By Moe Alsumidaie

TransCelerate recently announced a new initiative focused on eLabeling in clinical trials. The eLabels Initiative is expected to improve label usage for patients, streamline labeling approaches at sites and create opportunities to decrease timelines in the investigational supply chain resulting in cost efficiencies for sponsors.

How eSource is Transforming RbM

By Moe Alsumidaie

With the clinical trial industry’s focus on improving monitoring efficiency and leveraging a variety of risk-based monitoring (RbM) models, novel eClinical technologies are emerging to facilitate clinical trial monitoring productivity.

Maximizing Recruitment of Targeted Oncology Populations

By C. Meghann Howland

While some countries are more progressive in approaching this challenge by virtue of mandatory, free of charge, molecular testing on all patients, this varies greatly in other countries based on institutional policy and insurance reimbursement.

Data Analysis

Examining the Stats: The “One Time” Investigator

Do 50% of US investigators only conduct one clinical trial? Much of the misunderstanding behind this “one time” claim, which first surfaced in the 1990s, rests on a misunderstanding of the BMIS.

Adaptive Trial Designs Gaining Momentum

Faster go/no-go decisions is the primary driver of adaptive-design adoption by sponsors.

Sponsor Preference of CRO Experience in Orphan Drug Trials

By 2020, orphan drug sales are expected to make up 19% of prescription drug sales, excluding generics.


Business and People April 2015

By Miraj Barodia

New faces among the Pharma Industry rise the ranks.

eSource: RbM Evolution is Coupled with SDV Elimination

By Moe Alsumidaie

The emergence of risk-based monitoring (RbM) is creating a revolution in the way biopharmaceutical sponsors and CROs manage clinical trial quality.

eDiary System’s Importance in a Clinical Trial for Female Sexual Dysfunction

By Sheila Rocchio

Palatin Technologies is a biotech company focused on developing targeted, receptor-specific, peptide therapeutics for the treatment of diseases with significant, unmet medical needs and commercial potential.


Real World Evidence in a Clinical Trials World

With a growing need for post-marketing safety databases, and increased need to collect qualitative information from patients in the pre- and post-market of a drug the evidence gathering from clinical trials onward is expanding. 


Risk-Based Monitoring in Clinical Trials

As acceptance for risk-based monitoring grows, this e-Book examines next steps for sponsors and CROs. This e-Book offers case studies, practical tips, and applications to enhance the effectiveness of a risk-based monitoring strategy.


Clinical Trials Data Sharing and Disclosure

This e-Book features information from a recent conference of global thought-leaders in clinical data disclosure and transparency, which address current practices, potential challenges and solutions for pharmaceutical companies complying with the regulatory, ethical and legal issues around clinical trial data sharing.




eSource Data in Clinical Investigations Conference 2015

May 05, 2015
Wyndham Philadelphia Historic District, Philadelphia, PA, USA

2015 AAHRPP Conference

May 19, 2015
Hilton, Chicago, IL, USA